The Cypriot Competition Authority holds two pharmaceutical companies as having abused their dominant position in the vaccines market through quantitative reductions and the free distribution of vaccines (Panayotou / Wyeth Hellas / Phadisco)

The Cyprus Commission for the Protection of Competition (“CPC”) found the Wyeth Hellas A.E.B.E. Pharmaceutical Products (Cyprus branch) (“Wyeth”) and Phadisco Ltd (“Phadisco”) to have abused its dominant position in the market of pneumonococcus vaccines, in violation of article 6(1)(d) of the Protection of Competition Law 13(I) of 2008 (“Law 13(I)/2008”), following proceedings initiated on the basis of an official complaint submitted by Akis Panayiotou & Yios Ltd (“the complainant”). Following the relevant complaint, the CPC formulated an allegation against Wyeth and Phadisco the alleged violation of s. 6(1)(d) of Law 13(I)/2008, on behalf of Wyeth and Phadisco for abuse of their dominant position in the market of pneumonococcus vaccines 'Prenevar', as a result of quantitative reductions

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

Anastasios A. Antoniou, The Cypriot Competition Authority holds two pharmaceutical companies as having abused their dominant position in the vaccines market through quantitative reductions and the free distribution of vaccines (Panayotou / Wyeth Hellas / Phadisco), 19 May 2009, e-Competitions May 2009, Art. N° 26651

Visites 1285

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues